Generics in Italy industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Italy
Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Italy
Leading company profiles reveal details of key generics market players' global operations and financial performance
Add weight to presentations and pitches by understanding the future growth prospects of the Italy generics market with five year forecasts by both value and volume
Essential resource for top-line data and analysis covering the Italy generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.
Reasons to Buy
What was the size of the Italy generics market by value in 2016?
What will be the size of the Italy generics market in 2021?
What factors are affecting the strength of competition in the Italy generics market?
How has the market performed over the last five years?
How large is Italy's generics market in relation to its regional counterparts?
For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.
The Italian generics market is expected to generate total revenues of $1.2bn in 2016, representing a compound annual growth rate (CAGR) of 8.5% between 2012 and 2016.
Market consumption volume is forecast to increase with a CAGR of 5.1% between 2012 and 2016, to reach a total of 20.1% of total pharma volume in 2016.
The country's low generics volume share means that the market has plenty of room to expand in a country whose government is looking to save money on healthcare spending wherever realistically possible as it struggles with economic malaise.
Market value forecast
Market volume forecast
Market value forecast
Market volume forecast
Five Forces Analysis
Threat of substitutes
Degree of rivalry
Sandoz International GmbH
Teva Pharmaceutical Industries Limited
Related MarketLine research
Figure 1: Italy generics market value: $ billion, 2012-16(e)
Figure 2: Italy generics market volume: % of total pharma volume, 2012-16(e)
Figure 3: Italy generics market geography segmentation: % share, by value, 2016(e)
Figure 4: Italy generics market value forecast: $ billion, 2016-21
Figure 5: Italy generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in Italy, 2016
Figure 7: Drivers of buyer power in the generics market in Italy, 2016
Figure 8: Drivers of supplier power in the generics market in Italy, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in Italy, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in Italy, 2016
Figure 11: Drivers of degree of rivalry in the generics market in Italy, 2016
Figure 12: Mylan Inc.: revenues & profitability
Figure 13: Mylan Inc.: assets & liabilities
Figure 14: Sanofi SA: revenues & profitability
Figure 15: Sanofi SA: assets & liabilities
Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities
Table 1: Italy generics market value: $ billion, 2012-16(e)
Table 2: Italy generics market volume: % of total pharma volume, 2012-16(e)
Table 3: Italy generics market geography segmentation: $ billion, 2016(e)
Table 4: Italy generics market value forecast: $ billion, 2016-21
Table 5: Italy generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Mylan Inc.: key facts
Table 7: Mylan Inc.: key financials ($)
Table 8: Mylan Inc.: key financial ratios
Table 9: Sandoz International GmbH: key facts
Table 10: Sanofi SA: key facts
Table 11: Sanofi SA: key financials ($)
Table 12: Sanofi SA: key financials (EUR)
Table 13: Sanofi SA: key financial ratios
Table 14: Teva Pharmaceutical Industries Limited: key facts
Table 15: Teva Pharmaceutical Industries Limited: key financials ($)
Table 16: Teva Pharmaceutical Industries Limited: key financial ratios
Table 17: Italy size of population (million), 2012-16
Table 18: Italy gdp (constant 2005 prices, $ billion), 2012-16
Table 19: Italy gdp (current prices, $ billion), 2012-16
Table 20: Italy inflation, 2012-16
Table 21: Italy consumer price index (absolute), 2012-16
Table 22: Italy exchange rate, 2012-16
Single User License:
Corporate User License:
Mylan Inc., Sandoz International GmbH, Sanofi SA, Teva Pharmaceutical Industries Limited
Generics, MarketLine, Italy
select a license
NEWSLETTER BY CATEGORY
The report was very informative and gives me an interesting view on the Indian market.... "Area Sales Manager, Muhlen Sohn GmbH & Co. KG"
We would like to thank the entire team of Ken Research in showcasing professionalism in research and quick turnaround time. We have had multiple research reports from Ken Research. The deadline communicated for research was duly met. The research reports were covering many aspects in detail. This showcases their endeavor and care for client satisfaction and a strong understanding of the clients’ requirements. Thank you again for your help... "Group Vice President Strategy, Aliaxis"
I appreciate their diligence and determination in customizing the research project. The data proves to be valuable and accurate. I would, in future, definitely use their services again... "Technical Marketing Manager, Ascendis Health Limited"
I would like to thank Ken research team for meeting our report deliverables. The report is very good and we appreciate your well cooperation. ... "., Coldwell Banker - Riyadh "
The research you conducted was very helpful for us and the integrity of your research approach gave us great confidence in the data. Look forward to collaborating again in future... "International and Business Dev. Director, Duta Abadi Primantara"